HC Wainwright reiterated his buy recommendation for shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a report published Tuesday morning, Benzinga reports. The company currently has a $22.00 price target on the stock.
Other research analysts have also recently issued reports on the stock. BMO Capital Markets decreased their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and issued an outperform rating on the stock in a report on Tuesday. Wedbush reiterated an outperform rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday. Finally, Truist Financial assumed coverage on shares of Y-mAbs Therapeutics in a research note on Friday, June 28. They issued a buy rating and a $21.00 price target for the company. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $19.29.
Read our latest stock analysis on YMAB
Y-mAbs Therapeutics trading up 8.7%
NASDAQ YMAB opened at $10.82 on Tuesday. The company’s 50-day average price is $11.86 and its 200-day average price is $13.73. The stock has a market cap of $474.81 million, a P/E ratio of -22.08 and a beta of 0.66. Y-mAbs Therapeutics has a 12-month low of $4.60 and a 12-month high of $20.90.
Insider buying and selling at Y-mAbs Therapeutics
In other Y-mAbs Therapeutics news, insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction that occurred on Thursday, May 23. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at $3,024,853. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction that occurred on Thursday, May 23. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at $3,024,853. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Bo Kruse sold 31,371 shares of the company’s stock in a transaction dated Friday, May 31. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the sale, the CFO now directly owns 210,877 shares of the company’s stock, valued at $2,545,285.39. The disclosure regarding this sale can be found here. In the last ninety days, insiders sold 99,444 shares of the company’s stock, valued at $1,203,925. 21.50% of the shares are currently owned by insiders.
Hedge funds comment on Y-mAbs Therapeutics
Several hedge funds and other institutional investors have recently changed their holdings in YMAB. SG Americas Securities LLC increased its holdings in shares of Y-mAbs Therapeutics by 17.5% in the 4th quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock valued at $147,000 after purchasing an additional 3,210 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Y-mAbs Therapeutics by 4.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock valued at $178,000 after purchasing an additional 1,089 shares in the last quarter. Sapient Capital LLC bought a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at around $298,000. Federated Hermes Inc. increased its position in shares of Y-mAbs Therapeutics by 4,708.0% in the 4th quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock worth $303,000 after acquiring an additional 43,549 shares in the last quarter. Finally, Bailard Inc. acquired a new position in Y-mAbs Therapeutics in the 4th quarter valued at around $115,000. 70.85% of the shares are held by hedge funds and other institutional investors.
About Y-mAbs Therapeutics
(Get free report)
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, is focused on developing and commercializing antibody-based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor, for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
More information
Get daily news and reviews about Y-mAbs Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
